HopeAI , a Mayo Clinic Platform Accelerate company, is advancing how cancer clinical trials are designed and executed. At the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, HopeAI ...

DelveInsight's Tumor-Infiltrating Lymphocyte Therapies Market Size, Target Population, Competitive Landscape & Market ...

The risk was particularly high in men (21 per cent increase versus nine per cent in women) and in under-60s (24 per cent ...

American Cancer Society Cancer Action Network, American Cancer Society, CAMPAIGN, Congress ,funding for cancer research ...

Ovarian cancer is one of the most challenging malignancies in oncology. Despite advances in diagnosis and treatment, it is ...

Released positive topline data from the VIRAGE Phase 2b study of VCN-01 (zabilugene almadenorepvec); expanded data to be presented at the European Society for Medical Oncology (ESMO) 2025 Congress in ...

Pb]VMT-α-NET study update presented at the 2025 ASCO Annual Meeting, based on updated interim results from a Phase 1/2a study in neuroendocrine tumors. As of the April 30, 2025 data cut-off date: Four ...

Over the last ten years, cell-based immunotherapy has emerged as a promising approach for treating solid tumors. Several companies, including Iovance Biotherapeutics, Obsidian Therapeutics, ...

More than 45 patients enrolled in Emi-Le Phase 1 dose expansion cohorts in post-topoisomerase-1 inhibitor ADC (post-topo-1) triple-negative breast cancer (TNBC)Plan to report initial clinical data fro ...

Continuing his interview about these results, CEPHEUS lead investigator Saad Z. Usmani, MD, MBA, FACP, FASCO, highlights the minimal residual disease negativity findings.

Gross profit (GAAP) was $339,000 for the six months ended June 30, 2025, down from $799,000 in 2024, yielding a gross margin of 28% versus 46% for the six months ended June 30 in 2025 and 2024, ...